Phathom Pharmaceuticals, Inc.
PHAT
$4.41
$0.194.50%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8,001.47% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8,001.47% | -- | -- | -- | -- |
| Cost of Revenue | 4,674.25% | -- | -- | -- | -- |
| Gross Profit | 9,080.39% | -- | -- | -- | -- |
| SG&A Expenses | 146.48% | 195.74% | 137.93% | 62.39% | 16.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.05% | 118.07% | 74.04% | 27.44% | -2.58% |
| Operating Income | -65.84% | -99.84% | -67.47% | -25.87% | 2.97% |
| Income Before Tax | -65.84% | -91.70% | -60.67% | -26.56% | -1.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.84% | -91.70% | -60.67% | -26.56% | -1.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.84% | -91.70% | -60.67% | -26.56% | -1.96% |
| EBIT | -65.84% | -99.84% | -67.47% | -25.87% | 2.97% |
| EBITDA | -65.93% | -100.07% | -67.67% | -25.96% | 2.96% |
| EPS Basic | -37.69% | -48.61% | -16.99% | 9.39% | 22.99% |
| Normalized Basic EPS | -37.69% | -48.61% | -16.99% | 9.39% | 22.99% |
| EPS Diluted | -37.69% | -48.61% | -16.99% | 9.39% | 22.99% |
| Normalized Diluted EPS | -37.69% | -48.61% | -16.99% | 9.39% | 22.99% |
| Average Basic Shares Outstanding | 23.26% | 26.41% | 35.10% | 37.44% | 31.00% |
| Average Diluted Shares Outstanding | 23.26% | 26.41% | 35.10% | 37.44% | 31.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
